As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model. Clients purchasing this report between April and June 2020 will be getting a ‘free’ updated market data excel sheet between July and September 2020 accounting for the impact of COVID-19 on the market in the current year 2020 and forecast.

Global CAR-T cell therapy market is expected to register significant growth during the forecast period owing to increasing prevalence of cancer and growing pool of patients who are showing response failure towards alternative treatments. Rising clinical trials and development of new and effective therapy options is also acting as key growth drivers for global CAR-T cell therapy market. In addition to this, growing need for breakthrough therapeutic solutions and effectiveness of CAR-T cell therapy in treating cancer are expected to fuel the market growth through 2025.

Moreover, thriving immuno-oncology sector and increasing R&D expenditure is also augmenting the growth of global CAR-T cell therapy market. Also, various governments around the globe are taking initiatives to promote research for cell therapy in cancer. This is further expected to propel the market growth in the coming years. However, global CAR-T cell therapy market might also face some challenges. The side effects of CAR-T cell therapy may lead to neurological problems and cytokine release syndrome (CRS), which is might hamper the market growth. Also, the complicated manufacturing process of CAR-T cells makes it a costly treatment.

Global CAR-t cell therapy market can be segmented based on indication, targeted antigen, product type, end user and region. Based on indication, the market can be segmented into Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL) and others. Among them, Diffused Large B-cell Lymphoma (DLBCL) segment is expected to witness fastest CAGR during the forecast period owing to its high prevalence around the globe.

Regionally, North America dominated the global CAR-T cell therapy market in 2019 and is further expected to hold its dominance during the forecast period owing to increasing development and launch of new therapies for the treatment of cancer by key  healthcare and drug manufacturers in the region. Further, Europe is expected to be the second largest market for global CAR-T cell therapy through 2025 as the region is witnessing extensive research for development of cancer treatment therapies.

Major companies operating in global CAR-T cell therapy market include Kite Pharma (subsidiary of Gilead Sciences), AbbVie Inc., Bluebird Bio, Bristol Myers Squibb (BMS), Gilead Sciences, Inc., Cellectis, Servier Laboratories, Pfizer Inc., Merck KGaA, Juno Therapeutics, Amgen Inc., Intellia Therapeutics, Novartis International AG, Caribou Biosciences, Inc., Celyad, Bellicum Pharmaceuticals, Inc., Noile-Immune Biotech, Cartesian Therapeutics, Johnson & Johnson and Sangamo Therapeutics, Inc., among others. The market players are investing on extensive research & development activities to launch new targeted cell therapies to strengthen their positions in global market.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global CAR-T cell therapy market.
  • To forecast global CAR-T Cell Therapy market based on indication, targeted antigen, product type, end user, company and regional distribution.
  • To identify drivers and challenges for global CAR-T cell therapy market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global CAR-T cell therapy market.
  • To identify and analyze the profile of leading players operating in the global CAR-T cell therapy market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of CAR-T cell therapy companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global CAR-T cell therapy market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.


Key Target Audience:

  • CAR-T cell therapy drug manufacturers/ companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as CAR-T cell therapy drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global CAR-T cell therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global CAR-T Cell Therapy Market, By Indication:
    • Diffused Large B-cell Lymphoma (DLBCL)
    • Acute Lymphoblastic Leukemia (ALL)
    • Multiple Myeloma (MM)
    • Chronic Lymphocytic Leukemia (CLL)
    • Follicular Lymphoma (FL)
    • Others
  • Global CAR-T Cell Therapy Market, By Targeted Antigen:
    • CD 19
    • CD22
    • BCMA (B-Cell Maturation Antigen)
    • HER1
    • HER2
    • Meso
    • EGFRvlll
    • Others
  • Global CAR-T Cell Therapy Market, By Product Type:
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • JCAR017 (Lisocabtagene Maraleucel)
    • bb2121
  • Global CAR-T Cell Therapy Market, By End User:
    • Hospitals
    • Cancer Treatment Centers
    • Others
  • Global CAR-T Cell Therapy Market, By Region:
    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
      • Singapore
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global CAR-T Cell Therapy Market

4.    Executive Summary

5.    Voice of Customer

6.    Global CAR-T Cell Therapy Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Others)

6.2.2.     By Targeted Antigen (CD 19, CD22, BCMA (B-Cell Maturation Antigen), HER1, HER2, Meso, EGFRvlll, Others)

6.2.3.     By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), JCAR017 (Lisocabtagene Maraleucel), bb2121)

6.2.4.     By End User (Hospitals, Cancer Treatment Centers, Others)

6.2.5.     By Company (2019)

6.2.6.     By Region

6.3.  Product Market Map

7.    Asia-Pacific CAR-T Cell Therapy Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Indication

7.2.2.     By Targeted Antigen

7.2.3.     By Product Type

7.2.4.     By End User

7.2.5.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China CAR-T Cell Therapy Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Indication

7.3.1.2.2.             By Targeted Antigen

7.3.1.2.3.             By Product Type

7.3.1.2.4.             By End User

7.3.2.     India CAR-T Cell Therapy Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Indication

7.3.2.2.2.             By Targeted Antigen

7.3.2.2.3.             By Product Type

7.3.2.2.4.             By End User

7.3.3.     Japan CAR-T Cell Therapy Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Indication

7.3.3.2.2.             By Targeted Antigen

7.3.3.2.3.             By Product Type

7.3.3.2.4.             By End User

7.3.4.     South Korea CAR-T Cell Therapy Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Indication

7.3.4.2.2.             By Targeted Antigen

7.3.4.2.3.             By Product Type

7.3.4.2.4.             By End User

7.3.5.     Singapore CAR-T Cell Therapy Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Indication

7.3.5.2.2.             By Targeted Antigen

7.3.5.2.3.             By Product Type

7.3.5.2.4.             By End User

7.3.6.     Australia CAR-T Cell Therapy Market Outlook

7.3.6.1.         Market Size & Forecast

7.3.6.1.1.             By Value

7.3.6.2.         Market Share & Forecast

7.3.6.2.1.             By Indication

7.3.6.2.2.             By Targeted Antigen

7.3.6.2.3.             By Product Type

7.3.6.2.4.             By End User

8.    Europe CAR-T Cell Therapy Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Indication

8.2.2.     By Targeted Antigen

8.2.3.     By Product Type

8.2.4.     By End User

8.2.5.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France CAR-T Cell Therapy Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Indication

8.3.1.2.2.             By Targeted Antigen

8.3.1.2.3.             By Product Type

8.3.1.2.4.             By End User

8.3.2.     Germany CAR-T Cell Therapy Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Indication

8.3.2.2.2.             By Targeted Antigen

8.3.2.2.3.             By Product Type

8.3.2.2.4.             By End User

8.3.3.     United Kingdom CAR-T Cell Therapy Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Indication

8.3.3.2.2.             By Targeted Antigen

8.3.3.2.3.             By Product Type

8.3.3.2.4.             By End User

8.3.4.     Italy CAR-T Cell Therapy Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Indication

8.3.4.2.2.             By Targeted Antigen

8.3.4.2.3.             By Product Type

8.3.4.2.4.             By End User

8.3.5.     Spain CAR-T Cell Therapy Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Indication

8.3.5.2.2.             By Targeted Antigen

8.3.5.2.3.             By Product Type

8.3.5.2.4.             By End User

9.    North America CAR-T Cell Therapy Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Indication

9.2.2.     By Targeted Antigen

9.2.3.     By Product Type

9.2.4.     By End User

9.2.5.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States CAR-T Cell Therapy Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Indication

9.3.1.2.2.             By Targeted Antigen

9.3.1.2.3.             By Product Type

9.3.1.2.4.             By End User

9.3.2.     Mexico CAR-T Cell Therapy Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Indication

9.3.2.2.2.             By Targeted Antigen

9.3.2.2.3.             By Product Type

9.3.2.2.4.             By End User

9.3.3.     Canada CAR-T Cell Therapy Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Indication

9.3.3.2.2.             By Targeted Antigen

9.3.3.2.3.             By Product Type

9.3.3.2.4.             By End User

10.  South America CAR-T Cell Therapy Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Indication

10.2.2.  By Targeted Antigen

10.2.3.  By Product Type

10.2.4.  By End User

10.2.5.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil CAR-T Cell Therapy Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Indication

10.3.1.2.2.           By Targeted Antigen

10.3.1.2.3.           By Product Type

10.3.1.2.4.           By End User

10.3.2.  Argentina CAR-T Cell Therapy Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Indication

10.3.2.2.2.           By Targeted Antigen

10.3.2.2.3.           By Product Type

10.3.2.2.4.           By End User

10.3.3.  Colombia CAR-T Cell Therapy Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Indication

10.3.3.2.2.           By Targeted Antigen

10.3.3.2.3.           By Product Type

10.3.3.2.4.           By End User

11.  Middle East and Africa CAR-T Cell Therapy Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Indication

11.2.2.  By Targeted Antigen

11.2.3.  By Product Type

11.2.4.  By End User

11.2.5.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa CAR-T Cell Therapy Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Indication

11.3.1.2.2.           By Targeted Antigen

11.3.1.2.3.           By Product Type

11.3.1.2.4.           By End User

11.3.2.  Saudi Arabia CAR-T Cell Therapy Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Indication

11.3.2.2.2.           By Targeted Antigen

11.3.2.2.3.           By Product Type

11.3.2.2.4.           By End User

11.3.3.  UAE CAR-T Cell Therapy Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Indication

11.3.3.2.2.           By Targeted Antigen

11.3.3.2.3.           By Product Type

11.3.3.2.4.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  Kite Pharma (subsidiary of Gilead Sciences)

14.2.2.  AbbVie Inc.

14.2.3.  Bluebird Bio

14.2.4.  Bristol Myers Squibb (BMS)

14.2.5.  Gilead Sciences, Inc.

14.2.6.  Cellectis

14.2.7.  Servier Laboratories

14.2.8.  Pfizer Inc.

14.2.9.  Merck KGaA

14.2.10.                Juno Therapeutics

14.2.11.                Amgen Inc.

14.2.12.                Intellia Therapeutics

14.2.13.                Novartis International AG

14.2.14.                Caribou Biosciences, Inc.

14.2.15.                Celyad

14.2.16.                Bellicum Pharmaceuticals, Inc.

14.2.17.                Noile-Immune Biotech

14.2.18.                Cartesian Therapeutics

14.2.19.                Johnson & Johnson

14.2.20.                Sangamo Therapeutics, Inc.

15.  Strategic Recommendations

16. About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com